Latest News- Pulmonary Embolism Therapeutics Market: Hospitals is expected to lead the Application segment during 2025-2029

The Pulmonary Embolism Therapeutics Market is being driven by Growing risk of adverse health conditions

The Pulmonary Embolism Therapeutics Market is expected to grow at a CAGR of 11.7% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 16693.4 million. The global pulmonary embolism therapeutics market is experiencing significant growth in 2024, fueled by technological advancements in diagnostic and treatment modalities. The rising prevalence of pulmonary embolism, coupled with innovations in medical procedures, is shaping the market landscape. Cutting-edge diagnostic techniques, such as line-probe assays and bacteriophage-based assays, are enhancing diagnostic accuracy, enabling early detection and intervention. In the treatment sector, parenteral low-molecular-weight heparin and unfractionated heparin remain the primary anticoagulants. Thrombolytic therapy is being continually refined for improved efficacy, with newer techniques like ultrasound-assisted catheter-directed thrombolysis gaining popularity for patients with massive and intermediate-high sub-massive risk pulmonary embolism. Emerging approaches, such as extracorporeal membrane oxygenation (ECMO), direct aspiration, and fragmentation with aspiration, are showing promise for severe cases. 

Get more information on Pulmonary Embolism Therapeutics Market by requesting a sample report

Which Factors Are Causing a Surge in Market Growth?

The market is segmented based on

• Application
  • Hospitals
  • Ambulatory surgical centers
  • Research institutes
• Route Of Administration
  • Oral
  • Parenteral
• Drug Class
  • Direct oral anticoagulants (DOACs)
  • Heparins vitamin K
  • Antagonists
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Norway
  • Asia
    • China
    • Japan
  • Rest of World (ROW)

According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows: 

• Growing risk of adverse health conditions
• Increase in geriatric population
• Rise in research and development activities for pulmonary embolism therapeutics

However, the market also witnesses some limitations, which are as follows:

• Adverse effects of the therapeutics
• High cost involved in treatment of pulmonary diseases
• Lack of skilled professionals

Benefits of Buying Global Pulmonary Embolism Therapeutics Market Research Report by Technavio

Rich Experience: 20+ years leading global market research, trusted insights across industries.

Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.

Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.

Market Scope in Pulmonary Embolism Therapeutics Market Research Report

Find out which segment is leading the market by accessing the free PDF report

Research Analysis Overview

The Pulmonary Embolism (PE) therapeutics market encompasses various treatments for PE, including anti-Xa agents and thrombin inhibitors. Biologic therapies, thrombolytic doses, and DVT prophylaxis are also utilized. PE and DVT severity, radiology interpretation, and cardiopulmonary exercise testing are crucial factors. Thrombin generation, platelet activation, and coagulation cascade are key aspects of blood coagulation. PE can lead to pulmonary hypertension, right ventricular dysfunction, and post-thrombotic syndrome. Pharmaceutical research and drug development focus on clinical outcomes, patient safety, healthcare policy, public health, prevention strategies, health promotion, and gene therapy or targeted therapy. Thromboembolic events, PE severity, DVT severity, and PE diagnosis are significant considerations. Biomarkers for PE and DVT, such as D-dimer, are essential for diagnosis and monitoring. The market for PE therapeutics is expanding due to the increasing prevalence of PE and DVT, and the need for effective and safe treatments.

Market Research Overview

The Pulmonary Embolism (PE) Therapeutics Market is a significant segment of the global pharmaceuticals industry, encompassing companies involved in the research and development (R&D) or production of various PE treatment options, including thrombolytic therapy and anticoagulation therapy. Thrombolytic therapy, specifically catheter-directed thrombolysis, is an essential treatment modality for PE and Deep Vein Thrombosis (DVT). The global pharmaceuticals market, which includes manufacturers and providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services, is projected to experience growth due to demographic trends. With the aging population, the proportion of individuals over 60 years old is anticipated to increase significantly in both the US and Europe by 2030-2050, leading to a higher prevalence of PE and DVT, thereby fueling market expansion.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/